95233-37-7

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-Chlorophenyl)cyclohexanecarboxylic acid is used as a reactant for the synthesis of novel hydrazone derivatives, which are known for their antimicrobial properties. These hydrazone derivatives can be further developed into potential antimicrobial agents, addressing the growing need for new antibiotics and antifungal drugs to combat drug-resistant infections.
In the synthesis process, 4-(4-Chlorophenyl)cyclohexanecarboxylic acid can be combined with hydrazine or its derivatives to form the desired hydrazone compounds. The resulting hydrazone derivatives can exhibit broad-spectrum antimicrobial activity, making them valuable candidates for further research and development in the pharmaceutical field.

Upstream product

• 49708-48-7 4-(4-Chloro-phenyl)-cyclohex-3-enecarboxylic acid 
• 106-39-8 bromochlorobenzene 
• 874-61-3 4-oxocyclohexanecarboxylic acid 
• 91161-85-2 trans-4-(p-chlorophenyl)-1-acetyl-cyclohexane 
• 128208-09-3 methyl trans-4-(4-chlorophenyl)cyclohexane-1-carboxylate 
• 3618-03-9 methyl 4-hydroxycyclohexanecarboxylate 

Downstream Products

• 129719-64-8 2-[4-(4-chlorophenyl)-cyclohexyl]-3-chloro-1,4-naphthoquinone 
• 1093396-16-7 N-[(1-{[4-(4-chlorophenyl)cyclohexyl]carbonyl}piperidin-4-yl)methyl]-4-(5-cyano-7-isopropyl-1,3-benzoxazol-2-yl)benzamide 
• 94015-53-9 atovaquone 
• 930766-09-9 4-(4-chlorophenyl)cyclohexan-1-ol 
• 1100053-58-4 trans-2-[4-(4-cyclohexyl)chlorophenyl]-1,4-naphthoquinone 
• 1100053-59-5 2-[4-(4-chlorophenyl)cyclohexyl]-2,3-dichloro-2,3-dihydro-1,4-naphthoquinone 
• 95233-18-4 atovaquone 
• 153977-22-1 2-[4-(4-chlorophenyl)cyclohexyl]-3-chloro-1,4-naphthoquinone 
• 1203609-11-3 cis/trans-(4-(4-chlorophenyl)cyclohexyl)naphthalen-1,4-dione 
• 1071223-07-8 cis-2-[4-(4-chlorophenyl)cyclohexyl]-3-chloro-1,4-naphthoquinone 
• 1400902-37-5 (E)-2-(2-ethylbenzyl)-3-oxo-3-(4-phenylcyclohexyl)-propionic acid ethyl ester 
• 1400902-36-4 (E)-6-(4-phenylcyclohexyl)-2-thioxo-5-(3-trifluoromethylbenzyl)-2,3-dihydro-1H-pyrimidin-4-one 
• 1400902-33-1 (E)-3-oxo-3-(4-phenylcyclohexyl)-propionic acid ethyl ester 

Relevant academic research and scientific papers

A pharmaceutical intermediate 4 - (4 - chlorophenyl) cyclohexyl -1 - formic acid

The invention belongs to the field of preparation of drug intermediates and particularly relates to a synthesis method of a drug intermediate 4-(4-chlorphenyl) cyclohexyl-1-formic acid. The method comprises the following steps: firstly reacting a compound I with R2SO2Cl in the presence of an acid-binding agent to obtain a compound II; carrying out catalytic coupling reaction on the compound II and a Grignard reagent 4-chlorphenyl magnesium halide under the action of a catalyst to obtain a compound III; and finally hydrolyzing the compound III in alkali liquor to obtain a target product 4-(4-chlorphenyl) cyclohexyl-1-formic acid. According to the synthesis method, all steps in a reaction route are exclusive reactions; and ortho-position and meta-position problems in friedel-crafts reaction are overcome, so that the utilization rate of raw materials is high; the total yield is high; and the cost is low. A main body structure is constructed by a coupling technique, so that the problem that hydrolysate which is formed after a lot of lewis acid used in the friedel-crafts reaction is hydrolyzed needs to be subjected to special treatment is overcome; the method is environment-friendly; and industrialized production is facilitated.

Medicaments for the treatment of toxoplasmosis

The present invention relates to the use of 2-?4-(4-chlorophenyl)cyclohexyl!-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt or other physiologically funtional derivative thereof for the manufacture of a medicament for the treatment and/or prophylaxis of toxoplasmosis in animals, to pharmaceutical compositions for the treatment and/or prophylaxis of toxoplasmosis, comprising said compound as active ingredient and to a method of treating or preventing toxoplasmosis in an animal which comprises administering to said animal an effective amount of said compound.

Method for treating animals infected with Babesia spp.

The present invention relates to pharmaceutical compositions for the treatment and/or prophylaxis of protozoal infections caused by Kinetoplastida, Apicomplexa, Anaerobic protozoa and Mircosporidia comprising 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt or other functional derivative thereof as active ingredient and to a method of treating or preventing siad protozoal infections in an animal which comprises administering to said animal an effective amount of siad compound.

Use of 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-Naphthoquinone for the treatment of cancer

The present invention relates to the use of 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone or a physiologically acceptable salt or other physiologically functional derivative thereof for the manufacture of a medicament for the treatment of tumours in animals, to pharmaceutical compositions for the treatment of tumours in animals, to pharmaceutical compositions for the treatment of tumours, comprising said compound as active ingredient and to a method of treating tumours in an animal which comprises administering to said animal an effective amount of said compound.

Medicaments

A method and certain compositions for treating Pneumocystis carinii infections in a mammal by administering a certain naphthoquinone compound or physiologically acceptable salts thereof.

Naphthoquinone derivatives

Novel antiprotozoal naphthoquinones having the general formula STR1 (wherein either R1 is hydrogen and R2 is selected from C1-6 alkoxy, aralkoxy, C1-6 alkyl-C1-6 alkoxy, phenyl substituted by one or two groups selected from halogen and C1-6 alkyl, halogen and perhalo-C1-6 alkyl; or R1 and R2 are both C1-6 alkyl or phenyl; and n is 0 or 1) and salt thereof. The compounds of formula (I) are useful for the treatment or prophylaxis of protozoal diseases including malaria, theileriosis and coccidiosis. Various processes for preparing compounds of formula (I) are described.

1-(Trans-4-alkylcyclohexyl)-2-(trans-4'-(p-substituted phenyl) cyclohexyl)ethane and liquid crystal mixture

A compound represented by the general formula: STR1 where X is a halogen atom, an alkyl group having from 1 to 8 carbon atoms or a cyano group, and R is an alkyl group having from 1 to 8 carbon atoms.